Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed.

[1]  T. Lüscher,et al.  Therapeutic Implications , 2020, The Endothelium: Modulator of Cardiovascular Function.

[2]  G. Calin,et al.  MiR-200 family and cancer: From a meta-analysis view. , 2019, Molecular aspects of medicine.

[3]  Roghayeh Sheervalilou,et al.  A new insight on serum microRNA expression as novel biomarkers in breast cancer patients , 2019, Journal of cellular physiology.

[4]  M. Incoronato,et al.  Clinical Translatability of “Identified” Circulating miRNAs for Diagnosing Breast Cancer: Overview and Update , 2019, Cancers.

[5]  L. Saal,et al.  Refinement of breast cancer molecular classification by miRNA expression profiles , 2019, BMC Genomics.

[6]  C. Rolfo,et al.  Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy , 2019, Breast Cancer Research.

[7]  N. Tung,et al.  Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy , 2018, Annals of Surgical Oncology.

[8]  Wanli Liu,et al.  Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data , 2018, Journal of breast cancer.

[9]  S. Abhang,et al.  A Novel Strategy to Investigate Tissue‐Secreted Tumor Microenvironmental Proteins in Serum toward Development of Breast Cancer Early Diagnosis Biomarker Signature , 2018, Proteomics. Clinical applications.

[10]  D. Thanos,et al.  Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics , 2018, Cancer Immunology, Immunotherapy.

[11]  Xing Li,et al.  Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer , 2018, Journal of Cancer.

[12]  C. Chen,et al.  The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.

[13]  P. Fernández-Llama,et al.  Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy , 2018, Journal of diabetes research.

[14]  G. Hartmann,et al.  Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA , 2018, Oncotarget.

[15]  A. Jemal,et al.  Breast cancer statistics, 2017, racial disparity in mortality by state , 2017, CA: a cancer journal for clinicians.

[16]  M. Hummel,et al.  miR-99a reveals two novel oncogenic proteins E2F2 and EMR2 and represses stemness in lung cancer , 2017, Cell Death and Disease.

[17]  Fei Su,et al.  Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. , 2017, Human pathology.

[18]  Zhen-bo Feng,et al.  A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: An integrated study of 1,110 cases. , 2017, Oncology reports.

[19]  J. Freudenheim,et al.  Discovery and replication of microRNAs for breast cancer risk using genome-wide profiling , 2016, Oncotarget.

[20]  J. Linke,et al.  The St. Gallen surrogate classification for breast cancer subtypes successfully predicts tumor presenting features, nodal involvement, recurrence patterns and disease free survival. , 2016, Breast.

[21]  D. Closa,et al.  Involvement of exosomes in lung inflammation associated with experimental acute pancreatitis , 2016, The Journal of pathology.

[22]  C. Gong,et al.  Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer , 2016, EBioMedicine.

[23]  Wei Xu,et al.  miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. , 2016, Journal of the National Cancer Institute.

[24]  O. Olopade,et al.  Identification of a circulating MicroRNA signature to distinguish recurrence in breast cancer patients , 2016, OncoTarget.

[25]  Andreas Trumpp,et al.  Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. , 2016, Carcinogenesis.

[26]  Eduardo Andrés-León,et al.  Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. , 2015, Clinical chemistry.

[27]  E. Ng,et al.  Circulating cell-free miRNAs as biomarker for triple-negative breast cancer , 2015, British Journal of Cancer.

[28]  George A Calin,et al.  A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients , 2014, Clinical Cancer Research.

[29]  Hailong Xie,et al.  U6 is not a suitable endogenous control for the quantification of circulating microRNAs. , 2014, Biochemical and biophysical research communications.

[30]  Russell Bowler,et al.  The multiMiR R package and database: integration of microRNA–target interactions along with their disease and drug associations , 2014, Nucleic acids research.

[31]  T. Stopka,et al.  Oncogenic MicroRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum , 2014, BMC Cancer.

[32]  S. Ramón y. Cajal,et al.  miR-125b Acts as a Tumor Suppressor in Breast Tumorigenesis via Its Novel Direct Targets ENPEP, CK2-α, CCNJ, and MEGF9 , 2013, PloS one.

[33]  J. Chang-Claude,et al.  Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. , 2013, Clinical chemistry.

[34]  P. Tan,et al.  Identification of Circulating MicroRNA Signatures for Breast Cancer Detection , 2013, Clinical Cancer Research.

[35]  B. Burwinkel,et al.  Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures , 2013, Front. Genet..

[36]  Liang Chen,et al.  Role of Deregulated microRNAs in Breast Cancer Progression Using FFPE Tissue , 2013, PloS one.

[37]  Hongjiang Wang,et al.  Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer , 2012, PloS one.

[38]  Wenlin Huang,et al.  miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. , 2011, Cancer research.

[39]  M. L. Hastings,et al.  Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.

[40]  G. Leto,et al.  Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[41]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[42]  Dana Ron,et al.  Algorithmic Stability and Sanity-Check Bounds for Leave-One-Out Cross-Validation , 1997, Neural Computation.

[43]  Wei-Yin Loh,et al.  Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..